United Therapeutics CEO Rothblatt sells $5.05 million in stock By Investing.com

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (), sold 9,500 shares of common stock on July 24, 2026, for a total value of approximately $5.05 million. The shares were sold at prices ranging from $528.718 to $535.0256 per share. The sale comes after the stock has delivered a remarkable 73.55% return over the past year, though InvestingPro analysis suggests the shares are currently trading above their Fair Value, placing UTHR on the platform’s Most Overvalued list.

These transactions were conducted under a pre-arranged 10b5-1 trading plan, which Ms. Rothblatt adopted on November 7, 2025. As part of this plan, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $135.42 per share, totaling approximately $1.29 million, immediately prior to their sale.

Following these reported transactions, Ms. Rothblatt beneficially owns 324,443 shares indirectly through family trusts where she shares investment power. She also holds 40,513 shares directly. Additional indirect holdings include 166 shares held by her spouse, 249,108 shares in family trusts where her spouse is sole trustee or co-trustee, 45,596 shares in family trusts where her spouse shares investment power, and 8,902 shares in family trusts where she is sole trustee or co-trustee. Furthermore, she indirectly holds 274,910 stock options through a family trust. For deeper insights into UTHR’s valuation and 13+ additional InvestingPro Tips, investors can access the comprehensive Pro Research Report available for this $22.43 billion biotech company.

The 10b5-1 trading plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026.

In other recent news, United Therapeutics Corporation announced that the U.S. Food and Drug Administration has granted premarket approval for its LungFX lung perfusion device. This device is intended for the evaluation of donor lungs outside the body before transplantation. Additionally, TD Cowen has reiterated a Buy rating for United Therapeutics stock, setting a price target of $675.00. Meanwhile, BETA Technologies completed the first electric aircraft flights under the FAA’s eVTOL Integration Pilot Program, marking a significant milestone in electric aviation. These flights covered approximately 275 nautical miles across airports in Virginia and Maryland. Furthermore, Raymond James has issued an earnings preview for several biopharmaceutical companies, including Insmed, suggesting potential for sequential launch growth that could exceed 2026 consensus estimates. These developments highlight significant advancements and analyst perspectives in the biotech and aviation sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.